Nagy-Grocz G, Spekker E, Kortesi T, Laborc K, Bohar Z, Fejes-Szabo A
Life (Basel). 2025; 15(2).
PMID: 40003563
PMC: 11856001.
DOI: 10.3390/life15020155.
Ashina H, Christensen R, Hay D, Pradhan A, Hoffmann J, Reglodi D
Nat Rev Neurol. 2024; 20(11):660-670.
PMID: 39256637
DOI: 10.1038/s41582-024-01011-4.
Witzel R, Block A, Pollmann S, Oetzel L, Fleck F, Bonaterra G
Front Cardiovasc Med. 2023; 10:1264901.
PMID: 37900572
PMC: 10611464.
DOI: 10.3389/fcvm.2023.1264901.
Vu J, Luong L, Sanford D, Oh S, Kuc A, Pisegna R
Biology (Basel). 2023; 12(7).
PMID: 37508442
PMC: 10376325.
DOI: 10.3390/biology12071013.
Lu J, Piper S, Zhao P, Miller L, Wootten D, Sexton P
Int J Mol Sci. 2022; 23(15).
PMID: 35897648
PMC: 9331257.
DOI: 10.3390/ijms23158069.
Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism.
Fu Y, Liu S, Rodrigues R, Han Y, Guo C, Zhu Z
Int J Biol Sci. 2022; 18(11):4341-4356.
PMID: 35864952
PMC: 9295067.
DOI: 10.7150/ijbs.71134.
The VIP/VPAC1R Pathway Regulates Energy and Glucose Homeostasis by Modulating GLP-1, Glucagon, Leptin and PYY Levels in Mice.
Sanford D, Luong L, Vu J, Oh S, Gabalski A, Lewis M
Biology (Basel). 2022; 11(3).
PMID: 35336804
PMC: 8945135.
DOI: 10.3390/biology11030431.
Signal Transduction by VIP and PACAP Receptors.
Langer I, Jeandriens J, Couvineau A, Sanmukh S, Latek D
Biomedicines. 2022; 10(2).
PMID: 35203615
PMC: 8962308.
DOI: 10.3390/biomedicines10020406.
Potential Therapeutic Role of Pituitary Adenylate Cyclase-Activating Polypeptide for Dry Eye Disease.
Hirabayashi T, Shibato J, Kimura A, Yamashita M, Takenoya F, Shioda S
Int J Mol Sci. 2022; 23(2).
PMID: 35054857
PMC: 8775530.
DOI: 10.3390/ijms23020664.
VIP/PACAP signaling as an alternative target during hyperoxic exposure in preterm newborns.
Thaci Q, Recica S, Kryeziu I, Mitrokhin V, Kamkin A, Sopi R
Physiol Res. 2021; 70(4):489-499.
PMID: 34062074
PMC: 8820544.
DOI: 10.33549/physiolres.934638.
Pituitary Adenylate Cyclase-Activating Polypeptide: A Promising Neuroprotective Peptide in Stroke.
Fang Y, Ren R, Shi H, Huang L, Lenahan C, Lu Q
Aging Dis. 2020; 11(6):1496-1512.
PMID: 33269103
PMC: 7673855.
DOI: 10.14336/AD.2020.0626.
The Cell-Autonomous Clock of VIP Receptor VPAC2 Cells Regulates Period and Coherence of Circadian Behavior.
Hamnett R, Chesham J, Maywood E, Hastings M
J Neurosci. 2020; 41(3):502-512.
PMID: 33234609
PMC: 7821861.
DOI: 10.1523/JNEUROSCI.2015-20.2020.
Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy.
Duan J, Shen D, Zhou X, Bi P, Liu Q, Tan Y
Nat Commun. 2020; 11(1):4121.
PMID: 32807782
PMC: 7431577.
DOI: 10.1038/s41467-020-17933-8.
Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases.
Soles-Tarres I, Cabezas-Llobet N, Vaudry D, Xifro X
Front Cell Neurosci. 2020; 14:221.
PMID: 32765225
PMC: 7380167.
DOI: 10.3389/fncel.2020.00221.
Dosage sensitivity intolerance of VIPR2 microduplication is disease causative to manifest schizophrenia-like phenotypes in a novel BAC transgenic mouse model.
Tian X, Richard A, El-Saadi M, Bhandari A, Latimer B, Savage I
Mol Psychiatry. 2019; 24(12):1884-1901.
PMID: 31444475
DOI: 10.1038/s41380-019-0492-3.
Adrenalectomy impairs vasoactive intestinal peptide-induced changes in food intake and plasma parameters.
Garnica-Siqueira M, Martins A, Dos Stopa L, Souza C, Zaia D, Leite C
Endocrine. 2019; 65(3):675-682.
PMID: 31325084
DOI: 10.1007/s12020-019-02012-w.
Discovery of PACAP and its receptors in the brain.
Hirabayashi T, Nakamachi T, Shioda S
J Headache Pain. 2018; 19(1):28.
PMID: 29619773
PMC: 5884755.
DOI: 10.1186/s10194-018-0855-1.
Presence and Effects of Pituitary Adenylate Cyclase Activating Polypeptide Under Physiological and Pathological Conditions in the Stomach.
Reglodi D, Illes A, Opper B, Schafer E, Tamas A, Horvath G
Front Endocrinol (Lausanne). 2018; 9:90.
PMID: 29615974
PMC: 5868562.
DOI: 10.3389/fendo.2018.00090.
Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.
Haulund Vollesen A, Amin F, Ashina M
Neurotherapeutics. 2018; 15(2):371-376.
PMID: 29464574
PMC: 5935633.
DOI: 10.1007/s13311-017-0596-x.
Targeted Orexin and Hypothalamic Neuropeptides for Migraine.
Strother L, Srikiatkhachorn A, Supronsinchai W
Neurotherapeutics. 2018; 15(2):377-390.
PMID: 29442286
PMC: 5935635.
DOI: 10.1007/s13311-017-0602-3.